Kornimate/medical-research-clean huggingface dataset:
intranasal dexmedetomidine versus oral paracetamol as a pre-anaesthetic medication in pediatric age group

Conditions: Anxiety

Summary: pre-operative anxiety is a major problem in children because it produces undesired results on induction and postoperative outcome. dexmedetomidine is a highly specific alpha 2 adrenergic receptor agonist. studies suggest that dexmetomidine administration is safe as it is less invasive and have a short half-life. paracetamol is a potent physical pain killer. it also reduces psychological reactivity and blunts physical and social pain. adenotonsillectomy is one of the most common surgeries performed in pediatric age groups, so it is important to reduce pre-operative anxiety in those children.

pre-operative anxiety is a major problem in children because it produces undesired results on induction and postoperative outcome. dexmedetomidine is a highly specific alpha 2 adrenergic receptor agonist. studies suggest that dexmetomidine administration is safe as it is less invasive and have a short half-life. paracetamol is a potent physical pain killer. it also reduces psychological reactivity and blunts physical and social pain. adenotonsillectomy is one of the most common surgeries performed in pediatric age groups, so it is important to reduce pre-operative anxiety in those children. the objective of this descriptive study is to compare the efficacy of dexmedetomidine and paracetamol premedication, measuring the degree of anxiety in the children prepared for adenotonsillectomy when they are separated from their parents.

Eligibility criteria:
inclusion criteria: * the patients who are clinically free or with controlled medical condition \[asa i or asa ii\]. * age between 2 to 8 years. exclusion criteria: * asa iii or asa iv. * age greater than 8 years. * parents' refusal to participate in the study. * patients with obstructive sleep apnea. * patients with known allergy or hypersensitivity reaction to any of the drugs used in the study. * patients with nasal infection or nasal pathology.

Keywords: dexmedetomidine paracetamol preoperative anxiety
prognostic impact of programmed death ligand-1 expression in advanced endometrial cancer

Conditions: Endometrial Cancer

Summary: the aim of this study was to assess the frequency of pd-l1 expression in stage iii-iv ecs and to investigate its correlation impact with progression-free survival (pfs), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating cd8+ lymphocytes (tils)


Eligibility criteria:
inclusion criteria: * all patients consecutively enrolled from january 2004 to december 2014 treated for endometrial cancer * stage iii-iv endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci exclusion criteria: * a patient record captured outside the time frame from january 2004 to december 2014
rhtsh-thyroid ablation with 1850 mbq of 131i

Conditions: Thyroid Cancer

Summary: most patients with differentiated thyroid carcinoma (dtc) are treated with therapeutic doses of radioiodine (131i) after initial surgery (total or near total thyroidectomy), aimed to destroy microscopic residual normal or tumoral thyroid cells and to facilitate the early detection of tumor recurrence based on serum thyroglobulin (tg) measurement and 131i whole body scan (wbs) (1-5). recently, preparation of patients for thyroid ablation with rhtsh and 3700 mbq of 131i on l-thyroxine (l-t4) therapy has been approved in europe by the european medicines agency (emea) as an alternative to thyroid hormone withdrawal (6), after a randomized, controlled, multicenter study demonstrated that both methods of preparation are equally effective (with 100% rate of successful ablation) and that patients prepared with rhtsh received lower total body irradiation and experienced a better quality of life compared to those rendered hypothyroid (7). the present study was aimed to compare the efficacy of fixed activities of 1850 mbq versus 3700 mbq of 131i for post surgical thyroid ablation in dtc patients prepared with rhtsh (tshα, thyrogen®, genzyme therapeutics, cambridge, ma) on l-t4 therapy.

aim: recently, a multicenter study in differentiated thyroid cancer (dtc) patients showed that 3700 mbq of 131i after rhtsh stimulation had successful post-surgical thyroid ablation rate similar to that obtained after thyroid hormone withdrawal. we investigated whether 1850 mbq of 131i have a rate of successful ablation similar to 3700 mbq in patients prepared with rhtsh. methods: seventy-two patients with dtc were randomly assigned after surgery to receive 1850 mbq (group a, n: 36) or 3700 mbq (group b, n: 36) of 131i after rhtsh. the two groups were comparable for age, sex, histotype and tumor stage. one injection of 0.9 mg of rhtsh was administered for two consecutive days; 131i therapy was delivered 24 hours after the last injection. a post-therapy whole body scan (wbs) was performed 72 hours later. successful ablation was assessed 6-8 months after therapy. results: successful ablation, defined as no visible uptake in the diagnostic wbs after rhtsh stimulation, was achieved in 88.9% of group a and group b patients. basal and rhtsh-stimulated serum tg was undetectable (\ 300 gy). conclusion: our results demonstrate that therapeutic 131i activities of 1850 mbq are equally effective as 3700 mbq for thyroid ablation in dtc patients prepared with rhtsh, even in the presence of lymph node metastases.

Eligibility criteria:
inclusion criteria: * newly diagnosed differentiated thyroid cancer patients, more than 18 years old, recently treated by near total thyroidectomy were eligible for the study exclusion criteria: * evidence of distant metastases and/or significant local invasion

Keywords: thyroid cancer; rhtsh; thyroid ablation
secondary endolymphatic hydrops and vestibular schwannomas on 3 tesla mri

Conditions: Vestibular Schwannoma

Summary: endolymphatic hydrops is well known of the lay public in its primary form that is ménière disease. nowadays, the best w ay to approach it in vivo, is to use magnetic resonance imaging (mri). however, endolymphatic hydrops don't limit itself to its primary form but cover a whole range of pathologies. the hypothesis is that patients with vestibular schwannomas are more likely to develop secondary saccular hydrops. the aim is to compare high-resolution t2-weighted images of the saccule in patients followed up for vestibular schwannomas with healthy volunteers and histological sections from cadavers in order to identify its changes. the secondary purpose of the protocol is to determine if vestibular and audiometric abnormalities could be related to this secondary hydrops more specifically than to the tumor size and localisation.


Eligibility criteria:
inclusion criteria: * age\> 18, * subject having benefited from an mri with t2 high-resolution 3d sequence (fiesa) in the context of the diagnosis of vestibular schwannoma between 2008 and 2017 at the university hospitals of strasbourg, * subject who has agreed to the use of medical data for the purposes of this research. exclusion criteria: * refusal of the patient to participate in the study * insufficient imaging data, * tumors already treated, * atypical tumors with uncertain diagnosis, intra-labrinthic or intra-labyrinthine schwannomas, concomitant infectious or inflammatory pathology in the middle or inner ear. * impossibility of giving the subject informed information (difficulty understanding the subject,) * subject under the protection of justice * subject under guardianship or curatorship

Keywords: schwannoma saccular dilatation endolymphatic hydrops magnetic resonnance imaging vertigo
media, morphokinetics, and mosaicism

Conditions: Embryonic Mosaicism; Embryo Culture Media; Embryo Morphokinetics; Infertility

Summary: embryonic aneuploidy is the underlying etiology for the majority of failed implantation and miscarriage. preimplantation genetic screening (pgs) with transfer of a euploid embryo has been advocated as a strategy for increasing live birth rates with a single embryo transfer. culturing embryos to the blastocyst stage for trophectoderm biopsy is a requirement for pgs. several commercially-available single-step embryonic culture media with varying composition have been established for use in the ivf laboratory. early reports have suggested differences in clinical outcomes, such as aneuploidy and miscarriage rates, with distinct culture media currently in standard use. however, there have been no clinical trials demonstrating the superiority of any one commercially-available culture media formulation. as a result, clinics use media with varying composition based upon familiarity and cost.


Eligibility criteria:
inclusion criteria: all subjects planning blastocyst culture for preimplantation genetic screening (pgs) will be offered enrollment. antral follicle count (afc) \>8 male and female partner \> 18 years of age exclusion criteria: female partner age \>42 years of age cleavage stage biopsy
clinical evaluation of the levita robotic platform

Conditions: Bariatric Surgery Candidate; Cholelithiases; Other Disease

Summary: the purpose of this study is to evaluate the safety and feasibility of the levita robotic platform (lrp) used with the levita magnetic surgical system (mss)

prospective, multi-center, single-arm, open label study designed to assess the safety and feasibility of the use of the levita robotic platform with the levita magnetic surgical system in laparoscopic procedures.

Eligibility criteria:
inclusion criteria: * • subject is at least 18 years of age * subject is scheduled to undergo elective laparoscopic procedure * subject signs a written informed consent form (icf) to participate in the study prior to any study required procedures exclusion criteria: * • subjects with pacemakers, defibrillators, or other electromedical implants * subjects with ferromagnetic implants * subjects with significant comorbidities: cardiovascular, neuromuscular, chronic obstructive pulmonary disease, and urological disease (renal failure) * subjects with a clinical history of impaired coagulation confirmed by abnormal blood tests * subject has an anatomical abnormality or disease of intended target tissue noted after initiation of index procedure that would prevent device use * subject is pregnant or wishes to become pregnant during the length of study participation * subject is not likely to comply with the follow-up evaluation schedule * subject is participating in a clinical trial of another investigational drug or device
evaluation of long-term safety, and efficacy of brivaracetam (brv) used as adjunctive treatment in subjects with epilepsy

Conditions: Epilepsy

Summary: n01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of brivaracetam (brv); as well as the effect of brv on subjects' health-related quality of life and to explore the direct medical resource use for brv (for subjects entering n01372 from a study where pharmacoeconomic data was collected). brv will be used at doses up to maximum of 200 mg/day, as adjunctive treatment in subjects aged 16 years or older with epilepsy.

flexible dosing up to 200 mg/day, twice daily (10, 25 and 50 mg oral film-coated tablets). the study will continue until either regulatory approval of brv has been granted by any health authority in an indication of adjunctive treatment of epilepsy, or until the sponsor decides to close the study, or until the brv development is stopped by the sponsor.

Eligibility criteria:
inclusion criteria: * subject is male or female and 16 years or older. subjects under 18 years of age may be included only where legally permitted and ethically accepted * subjects having completed the treatment period of an applicable previous brv study, and have access to the present study * subject for whom the investigator believes a reasonable benefit from the long-term administration of brv may be expected * female subjects without childbearing potential (postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method * subjects must be able to take the oral film-coated tablets of brv exclusion criteria: * subject has developed hypersensitivity to any components of the investigational medicinal product (imp) or comparative drugs as stated in the protocol during the course of the prior study * severe medical, neurological, or psychiatric disorders, or laboratory values that may have an impact on the safety of the subject * poor compliance with the visit schedule or medication intake in the previous brv study * planned participation in any other clinical study of another investigational drug or device during this study * pregnant or lactating woman * any medical condition which, in the investigator's opinion, warrants exclusion * subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("yes") to either question 4 or question 5 of the columbia-suicide severity rating scale (c-ssrs) at the last visit of the previous study or at the entry visit of this study if not completed at the last visit of the previous study

Keywords: brivaracetam long-term follow-up epilepsy partial onset seizures adjunctive treatment
excimer light for alopecia areata

Conditions: Alopecia Areata

Summary: alopecia areata (aa) is a chronic autoimmune inflammatory disease causing nonscarring hair loss. many treatment modalities have been found to be helpful in aa, however, none on them cure the disease. uvb excimer light has recently emerged as a new therapeutic modality in many dermatologic diseases. there are no prospective randomized controlled trials evaluating the efficacy and safety of uvb excimer light in aa. we plan on conducting a prospective split lesion single-blinded randomized clinical trial to assess efficacy and safety of uvb excimer light in the treatment of aa.

alopecia areata (aa) is a chronic autoimmune inflammatory disease causing nonscarring hair loss. many treatment modalities have been found to be helpful in aa, however, none on them cure the disease. excimer laser has been shown to be effective in the treatment of aa in controlled studies. the main disadvantage of the previous studies evaluating excimer laser is choosing separate patches as a control which does not account for interlesional treatment response variability. uvb excimer light has recently emerged as a new therapeutic modality in many dermatologic diseases. however, there are only a few studies that evaluated the efficacy and safety of uvb excimer light in aa. those studies have shown that uvb excimer light is effective in the treatment of aa but none of them was conducted in a controlled fashion. there are no prospective randomized controlled trials evaluating the efficacy and safety of uvb excimer light in aa. we plan on conducting a prospective split lesion single-blinded randomized clinical trial to assess efficacy and safety of uvb excimer light in the treatment of aa. study objectives 1. to evaluate the potential for uvb excimer light to induce hair regrowth within aa patches. 2. to assess the side effect profile of uvb excimer light when used in the treatment of aa.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * subject has a patch of at least 12 cm2 on the scalp with no evidence of hair regrowth. * subject is willing and capable of cooperating to the extent and degree required by the protocol. exclusion criteria: * patients who received treatment for alopecia areata within the past 4 weeks. * patients with alopecia totalis or alopecia universalis. * patients with known photosensitivity like having polymorphous light eruption, connective tissue diseases, porphyria or xeroderma pigmentosum. * pregnancy or breast-feeding. * history of previous skin cancer. * patients that have participated in another investigational drug or device study within 30 days of enrollment.

Keywords: alopecia areata excimer uvb
study on optimal treatment strategy for elderly patients with high-risk complex aortic valve disease

Conditions: Aortic Valve Disease

Summary: aortic valve disease (avd) is the most common and age-related mortality in elderly patients with valvular heart disease (vhd). although transcatheter aortic valve replacement (tavr) has been recommended at a higher level in foreign guidelines, there are still many high-risk and severe elderly patients with vhd who have not received effective treatment because of many complications and untimely medical treatment. different from europe and the united states, the majority of patients with bicuspid aortic valve are in china, and the calcification is more serious. the current clinical evaluation system and treatment guidelines can not be effectively applied to the high-risk and complex elderly patients. therefore, the investigators should train and set up a valvular heart disease team, explore the technical difficulties of tavr treatment in such patients, establish emergency tavr operation mechanism, build a clinical evaluation system for high-risk and complex elderly patients with aortic valve disease in china, evaluate the curative effect periodically and further optimize the treatment strategy, so as to improve the quality of life and the meaning of life cycle of elderly patients with vhd in china great significance.


Eligibility criteria:
inclusion criteria: * • patients over 75 years old meet one of the following conditions. severe valvular heart disease as defined by echocardiography: 1. aortic stenosis, moderate or above, or valve area ≤1.0cm2, or maximal jet velocity ≥4.0m/sec, or mean pressure gradient ≥40mmhg, 2. aortic regurgitation, moderate or above, or jet width ≥65% of left ventricular outflow tract, or regurgitant volume≥60ml/beat, or regurgitant fraction ≥50%, exclusion criteria: * • patients cannot be followed up for any reasons. * •patients have been enrolled in this study
monitoring of fluoroscopy time on the dose delivered to the patient during vertebral cementoplasty procedures

Conditions: Vertebra Compression Fracture

Summary: the interventional radiology department of the strasbourg university hospital performs approximately 1,000 vertebral cementoplasties per year. this is one of the most practiced procedures in the department and therefore exposes the professionals in the room to significant annual cumulative doses of irradiation. the objective of the study is to evaluate the interest of continuous visual monitoring of the fluoroscopy time by the operator on the dose delivered to the patient during an interventional radiology procedure performed under fluoroscopic control. the chosen reference examination is a single-level vertebral cementoplasty, a standardized examination that is frequent enough to allow easy data collection


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * man or woman * patient cared for at the hus in interventional service for the realization of a vertebral cementoplasty of a single level between 01/06/2020 and 30/09/2020 * subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research. exclusion criteria: * patient who expressed their opposition to the reuse of their data for research purposes * vertebroplasties of more than one level * history of spinal surgery or vertebroplasty near the level concerned

Keywords: vertebra compression fracture vertebral cementoplasty fluoroscopy time fluoroscopic control single-level vertebral cementoplasty
intensive versus regular dosage for pd in aki.

Conditions: Peritoneal Dialysis; Acute Kidney Injury

Summary: this is a multicenter, pilot rct study, aiming to compare intensive dosage and regular dosage of pd for aki patients with indications for dialysis. aims of the study are to: examine the feasibility of the study, which aims to determine the efficacy and safety of intensive pd dose for aki patients as compared to regular pd dose. establish the appropriate workflow for pd treatment for aki patients.

the incidence of acute kidney injury (aki) is rapidly increasing worldwide, which partly due to greater recognition of aki, more exposure to various nephrotoxins and an ageing population with increased burden of non-infectious chronic disease. intermittent hemodialysis (ihd) or continuous renal replacement therapy (crrt) (i.e. venous-venous hd or hemofiltration) are the most-commonly modalities applied for acute kidney injury (aki) patients in both developed and developing countries. by contrast, the use of peritoneal dialysis (pd) has been rare. there are no consensus on the ideal dosage and target of adequacy for pd in aki. therefore, we are to perform a multicenter, pilot rct study, aiming to compare intensive dosage and regular dosage of pd for aki patients with indications for dialysis. if successful, this strategy is expected to enhance the remedy rate of akf patients, especially in developing regions/countries.

Eligibility criteria:
inclusion criteria: * age older than 14 years; * be diagnosed as aki according to kdigo recommendation; * having indications for renal replacement therapy. exclusion criteria: * having contraindications to peritoneal dialysis; * functional azotemia; * hypercatabolic status; * previous ckd history (baseline egfr\<60ml/min/1.73m2 or proteinuria); * psychological disorder or communication barrier; * pregnancy; * refusing to receive dialysis therapy. * receiving mechanical ventilation.

Keywords: acute kidney injury peritoneal dialysis dosage